PortfoliosLab logoPortfoliosLab logo

Documentation

Upgrade your plan
GERM vs. FBT
Performance
Return for Risk
Dividends
Drawdowns
Volatility

GERM vs. FBT

Last updated Apr 2, 2026

Compare and contrast key facts about Amplify Treatments, Testing and Advancements ETF (GERM) and First Trust Amex Biotechnology Index (FBT).

GERM and FBT are both exchange-traded funds (ETFs), meaning they are traded on stock exchanges and can be bought and sold throughout the day. GERM is a passively managed fund by Amplify that tracks the performance of the Prime Treatments, Testing and Advancements Index. It was launched on Jun 17, 2020. FBT is a passively managed fund by First Trust that tracks the performance of the NYSE Arca Biotechnology Index. It was launched on Jun 23, 2006. Both GERM and FBT are passive ETFs, meaning that they are not actively managed but aim to replicate the performance of the underlying index as closely as possible.

Performance

GERM vs. FBT - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Amplify Treatments, Testing and Advancements ETF (GERM) and First Trust Amex Biotechnology Index (FBT). The values are adjusted to include any dividend payments, if applicable.

Loading graphics...

GERM vs. FBT - Yearly Performance Comparison

2026 (YTD)20252024
GERM
Amplify Treatments, Testing and Advancements ETF		0.00%0.00%0.00%
FBT
First Trust Amex Biotechnology Index		-1.95%24.25%1.65%

Returns By Period

GERM

1D
0.00%
1M
0.00%
YTD
0.00%
6M
0.00%
1Y
0.00%
3Y*
—
5Y*
—
10Y*
—

FBT

1D
0.84%
1M
-1.41%
YTD
-1.95%
6M
9.21%
1Y
23.14%
3Y*
9.56%
5Y*
4.87%
10Y*
8.68%
*Multi-year figures are annualized to reflect compound growth (CAGR)

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Amplify Treatments, Testing and Advancements ETF

First Trust Amex Biotechnology Index

Often compared with GERM:
GERM vs. SBIOGERM vs. EQRRGERM vs. GDOCGERM vs. MDEVGERM vs. ARKGGERM vs. MNY.TOGERM vs. BTEC
Often compared with FBT:
FBT vs. XBIFBT vs. BBHFBT vs. IBBFBT vs. BBPFBT vs. FXHFBT vs. PBEFBT vs. HELX

GERM vs. FBT - Expense Ratio Comparison

GERM has a 0.68% expense ratio, which is higher than FBT's 0.57% expense ratio.

GERM
Amplify Treatments, Testing and Advancements ETF
FBT
First Trust Amex Biotechnology Index

Return for Risk

GERM vs. FBT — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.
GERM
FBT
FBT Risk / Return Rank: 4848
Overall Rank
FBT Sharpe Ratio Rank: 5050
Sharpe Ratio Rank
FBT Sortino Ratio Rank: 5252
Sortino Ratio Rank
FBT Omega Ratio Rank: 4646
Omega Ratio Rank
FBT Calmar Ratio Rank: 4949
Calmar Ratio Rank
FBT Martin Ratio Rank: 4141
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

GERM vs. FBT - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Amplify Treatments, Testing and Advancements ETF (GERM) and First Trust Amex Biotechnology Index (FBT). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.

GERM vs. FBT - Sharpe Ratio Comparison

Loading graphics...

Sharpe Ratios by Period

GERMFBTDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

—

0.95

—

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

—

0.23

—

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

—

0.36

—

Sharpe Ratio (All Time)

Calculated using the full available price history

—

0.50

—

Dividends

GERM vs. FBT - Dividend Comparison

Neither GERM nor FBT has paid dividends to shareholders.

TTM20252024202320222021202020192018201720162015
GERM
Amplify Treatments, Testing and Advancements ETF		0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
FBT
First Trust Amex Biotechnology Index		0.00%0.00%0.71%0.00%0.00%1.37%0.00%0.00%0.00%0.00%0.00%0.12%

Drawdowns

GERM vs. FBT - Drawdown Comparison

The maximum GERM drawdown since its inception was 0.00%, smaller than the maximum FBT drawdown of -40.51%. Use the drawdown chart below to compare losses from any high point for GERM and FBT.

Loading graphics...

Drawdown Indicators

GERMFBTDifference

Max Drawdown

Largest peak-to-trough decline

0.00%

-40.51%

+40.51%

Max Drawdown (1Y)

Largest decline over 1 year

0.00%

-14.26%

+14.26%

Max Drawdown (5Y)

Largest decline over 5 years

—

-29.05%

—

Max Drawdown (10Y)

Largest decline over 10 years

—

-32.37%

—

Current Drawdown

Current decline from peak

0.00%

-8.73%

+8.73%

Average Drawdown

Average peak-to-trough decline

0.00%

-11.22%

+11.22%

Ulcer Index

Depth and duration of drawdowns from previous peaks

0.00%

4.71%

-4.71%

Volatility

GERM vs. FBT - Volatility Comparison

The current volatility for Amplify Treatments, Testing and Advancements ETF (GERM) is 0.00%, while First Trust Amex Biotechnology Index (FBT) has a volatility of 8.73%. This indicates that GERM experiences smaller price fluctuations and is considered to be less risky than FBT based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Loading graphics...

Volatility by Period

GERMFBTDifference

Volatility (1M)

Calculated over the trailing 1-month period

0.00%

8.73%

-8.73%

Volatility (6M)

Calculated over the trailing 6-month period

0.00%

15.54%

-15.54%

Volatility (1Y)

Calculated over the trailing 1-year period

0.00%

24.78%

-24.78%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

0.00%

21.71%

-21.71%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

0.00%

24.06%

-24.06%